This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore content

  

MaterialsVideos
Let's connectLet's ConnectPfizer medical information
Novel Therapieshemophilia_logo.pngNovel TherapiesEventshemophilia_logo.pngAboutAboutWhat is Hemophilia?Hemophilia Burden of DiseaseHeritageDiagnosisDiagnosisSigns and SymptomsInvestigationsTreatmentTreatmentTreatment OptionsNovel TherapiesSupport & ResourcesSupport & ResourcesPatient Support ResourcesHemMobile®Patient Support LeafletsEvents

Hemophilia Burden of Disease

In addition to causing visible bleeding and bruising, hemophilia can cause bleeding into joints and muscles, which may be subclinical.1

Severity

The severity of bleeding manifestations in hemophilia generally correlates with the degree of the clotting factor deficiency.1,2


Adapted from Srivastava A, et al. 2020.

Although residual FVIII/FIX activity level accounts for around 70% of the bleeding phenotype, the remaining 30% are potentially related to other unexplained individual variables.3

Sites of Bleeding

Hemophilia not only causes visible bleeding and bruises, which sometimes require surgical intervention, but also causes internal bleeding. Indeed, most bleeding in hemophilia occurs internally, into the muscles or joints.1

Acute joint bleeds can cause permanent damage to the joints or hemophilic arthropathy.1
Bleeding into the abdomen or brain can be serious or life-threatening.4

Common Locations of Muscle and Joint Bleeds5

Adapted from World Federation of Hemophilia.5

In addition to these complications, some patients with hemophilic arthropathy may experience acute to chronic pain.6 A survey of 119 Italian patients (including 76% with severe hemophilia) found that 61% of the patients reported experiencing pain; 71% qualified this pain as ‘chronic’, 69% as ‘acute’ and 8% as ‘postoperative’, and the pain was considered ‘severe’ in 65% of cases.6​​​​​​​

  

FVIII, factor VIII; FIX, factor IX.

  

References:

Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition [published correction appears in Hemophilia. 2021;27(4):699]. Hemophilia. 2020;26(suppl 6):1-158.Iorio A, Stonebraker JS, Chambost H, et al; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540-546.Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; subcommittee on factor viii, factor ix and rare coagulation disorders. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018;16(10):2106-2110.Do you know the signs of these 6 types of bleeds? Hemaware. Accessed April 27, 2022. https://hemaware.org/bleeding- disorders-z/do-you-know-signs-these-6-types-bleeds What is hemophilia? World Federation of Hemophilia. Accessed April 27, 2022. http://www1.wfh.org/publications/files/pdf-1324.pdfTagliaferri A, Franchini M, Rivolta GF, et al. Pain assessment and management in hemophilia: a survey among Italian patients and specialist physicians. Hemophilia. 2018;24(5):766-773.

   

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

PP-BEN-IND-0024  22/7/22

About
Support Your Patients

Pfizer is committed to supporting you and your patients with hemophilia.
Learn more about the patient resources available to support your patients.

Patient support resources


Diagnosis

Refresh your knowledge about the symptoms and diagnosis of hemophilia and understand why early diagnosis and treatment may be important for your patients.

Signs and symptoms


Treatment

Understand the current treatment options and recommendations for patients with hemophilia A and B.
 

Treatment options

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-BEN-IND-0024

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​